Literature DB >> 18784150

Histopathology and bronchoalveolar lavage.

R M Silver1, A U Wells.   

Abstract

Although neither lung biopsy nor bronchoalveolar lavage (BAL) is recommended for routine clinical use in patients with SSc, studies employing lung biopsy material and BAL fluid (BALF) have provided insight into the pathogenesis of scleroderma-associated interstitial lung disease (SSc-ILD). Most often, SSc-ILD is classified as a non-specific interstitial pneumonia, with abundant myofibroblasts and evidence of both epithelial cell and endothelial cell injury. Recently, SSc-ILD fibroblasts have been shown to express reduced levels of the caveolin-1 protein which, in turn, may lead to activation of the signalling molecules associated with increased collagen production and overexpression of alpha-smooth muscle cell actin (alpha-SMA). BALF often contains increased numbers of inflammatory cells as well as myofibroblasts expressing alpha-SMA. Analysis of BALF suggests an imbalance between pro-fibrotic and anti-fibrotic factors, e.g. an overabundance of TGF-beta, connective tissue growth factor (CTGF), PDGF, leucotriene B4, etc. and in some cases a deficiency of hepatocyte growth factor, 15-hydroxyeicosatetraenoic acid (15-HETE), lipoxin A, etc. Until the pathogenesis is fully understood, lung biopsy and BAL will remain useful research tools to better understand the inflammatory and fibrosing processes that underlie SSc-ILD.

Entities:  

Mesh:

Year:  2008        PMID: 18784150      PMCID: PMC2722810          DOI: 10.1093/rheumatology/ken272

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  21 in total

1.  Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway.

Authors:  G S Bogatkevich; E Tourkina; R M Silver; A Ludwicka-Bradley
Journal:  J Biol Chem       Date:  2001-09-28       Impact factor: 5.157

2.  Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung.

Authors:  J Behr; C Vogelmeier; T Beinert; M Meurer; F Krombach; G König; G Fruhmann
Journal:  Am J Respir Crit Care Med       Date:  1996-08       Impact factor: 21.405

3.  Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis.

Authors:  M Beon; R A Harley; A Wessels; R M Silver; A Ludwicka-Bradley
Journal:  Clin Exp Rheumatol       Date:  2004 Nov-Dec       Impact factor: 4.473

4.  Opposing effects of protein kinase Calpha and protein kinase Cepsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling.

Authors:  Elena Tourkina; Pal Gooz; Jaspreet Pannu; Michael Bonner; Dimitri Scholz; Sharon Hacker; Richard M Silver; Maria Trojanowska; Stanley Hoffman
Journal:  J Biol Chem       Date:  2005-02-03       Impact factor: 5.157

5.  Evaluation and management of scleroderma lung disease using bronchoalveolar lavage.

Authors:  R M Silver; K S Miller; M B Kinsella; E A Smith; S I Schabel
Journal:  Am J Med       Date:  1990-05       Impact factor: 4.965

6.  Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

Authors:  Demosthenes Bouros; Athol U Wells; Andrew G Nicholson; Thomas V Colby; Vlasis Polychronopoulos; Panos Pantelidis; Patricia L Haslam; Dimitris A Vassilakis; Carol M Black; Roland M du Bois
Journal:  Am J Respir Crit Care Med       Date:  2002-06-15       Impact factor: 21.405

7.  Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of patients with scleroderma.

Authors:  A Ludwicka; M Trojanowska; E A Smith; M Baumann; C Strange; J H Korn; T Smith; E C Leroy; R M Silver
Journal:  J Rheumatol       Date:  1992-11       Impact factor: 4.666

8.  Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor.

Authors:  T Ohba; J K McDonald; R M Silver; C Strange; E C LeRoy; A Ludwicka
Journal:  Am J Respir Cell Mol Biol       Date:  1994-04       Impact factor: 6.914

9.  Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage.

Authors:  R M Silver; J F Metcalf; J H Stanley; E C LeRoy
Journal:  Arthritis Rheum       Date:  1984-11

10.  Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients.

Authors:  Irina G Luzina; Sergei P Atamas; Robert Wise; Fredrick M Wigley; Jung Choi; Hui Qing Xiao; Barbara White
Journal:  Arthritis Rheum       Date:  2003-08
View more
  4 in total

Review 1.  Pathogenesis of pulmonary fibrosis in systemic sclerosis: lessons from interstitial lung disease.

Authors:  Kristen L Veraldi; Eileen Hsu; Carol A Feghali-Bostwick
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

Review 2.  Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.

Authors:  Tanjina Akter; Richard M Silver; Galina S Bogatkevich
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

Review 3.  [Interstitial lung disease in collagen vascular diseases. Diagnostic and therapeutic implications of non-specific interstitial pneumonia].

Authors:  A Schnabel; M Reuter
Journal:  Z Rheumatol       Date:  2009-10       Impact factor: 1.372

Review 4.  The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis.

Authors:  Nicola Farina; Giovanni Benanti; Giacomo De Luca; Anna Palmisano; Giovanni Peretto; Sara Tomassetti; Veronica Giorgione; Ornella Forma; Antonio Esposito; Silvio Danese; Lorenzo Dagna; Marco Matucci-Cerinic; Corrado Campochiaro
Journal:  J Multidiscip Healthc       Date:  2022-04-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.